South Korea begins approval process for AstraZeneca vaccine

[Hamartia Antidote]

Korea begins approval process for AstraZeneca vaccine

AstraZeneca’s COVID-19 vaccine (AZD1222) will be reviewed for potential approval in South Korea within the next 40 days, Korea’s Ministry of Food and Drug Safety announced Monday. According to the Drug Ministry, AstraZeneca Korea has submitted applications for approval for its vaccine to be...

www.koreaherald.com

AstraZeneca’s COVID-19 vaccine (AZD1222) will be reviewed for potential approval in South Korea within the next 40 days, Korea’s Ministry of Food and Drug Safety announced Monday.

According to the Drug Ministry, AstraZeneca Korea has submitted applications for approval for its vaccine to be manufactured locally under a contract with SK Bioscience and for more of the vaccine to be shipped from manufacturers in Italy, the US and the UK.

AstraZeneca is required to submit further documents proving that the vaccine used in its clinical trials is of identical quality to that manufactured by SK Bioscience.

In the meantime, the Drug Ministry will undergo a rolling review of the applications to increase the time-efficiency of the approval process.

AstraZeneca’s vaccine is currently undergoing phase 3 clinical trials in some 10 countries including the UK, Brazil and the US. They are expected to be complete by September.

Once the trial is over the company is required to submit a 12-month follow-up detailing any reported side effects.

AstraZeneca’s is a viral vector vaccine, which stimulates the body to create neutralizing antibodies.